A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults With Symptomatic Human Rhinovirus Infection

Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults With Symptomatic Human Rhinovirus Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Vapendavir (Primary)
  • Indications Rhinovirus infections
  • Focus Therapeutic Use
  • Acronyms SPIRITUS
  • Sponsors Aviragen Therapeutics
  • Most Recent Events

    • 24 May 2017 Baseline characteristics presented at the 113th International Conference of the American Thoracic Society
    • 13 Feb 2017 Top-line results published in an Aviragen Therapeutics media release.
    • 13 Feb 2017 According to an Aviragen Therapeutics media release, this trial was conducted at approximately 68 sites in North America and Europe.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top